TTR and amyloidosis: For example, two therapeutics based on RNA interference (RNAi) were approved, ONPATTRO® (Partisiran) for polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis in 2018 [1], and GIVLAARITM (Givosiran) for acute hepatic porphyria (AHP) in 2019 [2].